Charité University Hospital

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Coronary artery disease1 trial
• Epilepsy1 trial
• Head and neck cancer1 trial
• Liver cirrhosis1 trial
• Migraine1 trial
• Nephrotic syndrome1 trial

Phase

• Phase 21 trial
• Phase 31 trial

Status

• Active, not recruiting2 trials
• Recruiting2 trials
• Completed1 trial
• Not yet recruiting1 trial
• Terminated1 trial

Lead sponsor

• European Foundation for Study of Chronic Liver Failure1 trial
• Helsinki University Central Hospital1 trial
• Matthias Friedrich1 trial
• Prof. Dr. Paul Brinkkoetter1 trial
• Rehaler1 trial
• and 2 more

Running trials

• Not yet recruiting

  Individualized Radiation Dose Prescription in HNSCC Based on F-MISO-PET Hypoxia-Imaging

  NCT03865277· Phase 2· Technische Universität Dresden· Source

  Contact: Volker Budach, Prof.

• Active, not recruiting

  Effects of Sedation, TEmperature and Pressure After Cardiac Arrest and REsuscitation on Major Adverse Kidney Events (STEPCARE-MAKE)

  NCT07579390· Helsinki University Central Hospital· Source

• Recruiting

  Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs

  NCT04613921· European Foundation for Study of Chronic Liver Failure· Source

  Contact: Cornelius Engelmann

• Active, not recruiting

  Breathing-Maneuver-Induced Myocardial Oxygenation Reserve Validated by FFR (B-MORE)

  NCT04126148· Matthias Friedrich· Source

• Recruiting

  The FOrMe Registry (The German Focal Segmental Glomerulosclerosis and Minimal Change Disease Registry)

  NCT03949972· Prof. Dr. Paul Brinkkoetter· Source

  Contact: Jan P. Halbritter, MD, Prof.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Head and neck cancer1 recruiting
• Liver cirrhosis1 recruiting
• Nephrotic syndrome1 recruiting

Closed trials

• Terminated

  PArtial REbreathing for Migraine With Aura 1

  NCT05546385· Rehaler· Source

• Completed

  Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures

  NCT05067634· Phase 3· SK Life Science, Inc.· Source